Zelluna ASA has announced a contemplated private placement to raise NOK 50-55 million in gross proceeds, alongside a retail offering of new shares through PrimaryBid, with the aim of raising up to the NOK equivalent of EUR 1 million. The funds will be used to initiate a phase I clinical trial for the company's lead asset, ZI-MA4-1, and to generate initial patient data by mid-2026. The private placement will be conducted at an offer price of NOK 10 per share and is primarily targeted at investors meeting specific exemption criteria, with a separate tranche available for board members and employees. The offering is expected to support Zelluna's advancement of its 'off-the-shelf' TCR-NK cell therapy for cancer treatment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zelluna ASA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001136689-en) on November 03, 2025, and is solely responsible for the information contained therein.